# US 2006/0069081 A1 · Carbapenem antibacterials with gram-negative activity and processes for their preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0069081 A1
- Document ID: US20060069081A1
- Status: Published application
- Kind: A1
- Application number: 11/150,428
- Filed: 2005-06-10
- Published: 2006-03-30
- Earliest claimed: 2004-06-10
- Assignees: FOB Synthesis, Inc.
- Inventors: Woo-Baeg Choi; Ewa Kowalik
- Web page: https://patentgrep.com/patent/US20060069081A1

## CPC

- C07D 477/14: with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.

## Claims

### Claim 1

A carbapenem compound of the formula I:
or pharmaceutically acceptable salts thereof, wherein:
R is H or alklyl;
R1 is H or alkyl;
M is H or a group such that CO2M is a carboxylic acid, a carboxylate anion, a pharmaceutically acceptable ester group, or a carboxylic acid protected by a protecting group;
P is selected from the group consisting of hydrogen, hydroxyl, halogen or hydroxyl protected by a hydroxyl protecting group; and
Y1 and Y2 are each independently selected from the group consisting of hydrogen; halogen; —CN; —NO2; NRaRb; —ORc; —SRc; —C(O)NRaRb; —C(O)ORh; S(O)Rc; —SO2Rc; —SO2NRaRb; —NRaSO2Rb; —C(O) Ra; OC(O)NRaRb; —NRaC(O)NRbRc; —NRaCO2Rh; —OCO2Rh; NRaC(O)Rb; C1-6 straight- or branched-chain alkyl that are substituted or unsubstituted with one to four Rd groups with or without saturation; alkylaryl, -A-(CH2)n-Q and C3-7 cycloalkyl, substituted or unsubstituted with one to four Rd groups, wherein:
A is O, S, NH, NCH3, NR, or —CH2—;
n is 0, 1, 2 or 3;
each Ra, Rb and Rc is independently selected from hydrogen, —C1-6 straight- or branched-chain alkyl, unsubstituted or substituted with one to four Rd groups, or —C3-7 cycloalkyl, unsubstituted or substituted with one to four Rd groups;
or Ra and Rb taken together with any intervening atoms is a 4-6 membered saturated ring optionally interrupted by one or more of O, S, NRc, or —C(O)—, the ring being unsubstituted or substituted with one to four Ri groups;
or Rb and Rc taken together with any intervening atoms is a 4-6 membered saturated ring optionally interrupted by one to three of O, S, NRa, with Ra as defined above, or —C(O)—, the ring being unsubstituted or substituted with one to four Ri groups;
each Rd is independently halogen; —CN; —NO2; —NReRf; —ORg; —SRg; —CONReRf; —COORg; —SORg; —SO2Rg; —SO2NReRf; —NReSO2Rf; —CORe; —NReCORf; —OCORe; —OCONReRfl NReCONRfRg; —NReCO2Rh; —OCO2Rh; —C(NRe)NRfRg; NReC(NH)NRfRg or —NReC(NRf)Rg;
each Re, Rf and Rg is selected from hydrogen; —Rh; —C1-6 straight- or branched-chain alkyl unsubstituted or substituted with one to four Ri groups or Re and Rf taken together with any intervening atoms is a 4-6 membered saturated ring optionally interrupted by one to three of O, S, —C(O)— or NRg with Rg as defined above, the ring being unsubstituted or substituted with one to four Ri groups;
each Ri is independently selected from halogen; —CN; —NO2; phenyl; —NHSO2Rh; —ORh, —SRh; —N(Rh)2; —N+(Rh)3; —C(O)N(Rh)2; SO2N(Rh)2; heteroaryl; heteroarylium; —CO2Rh; —C(O)Rh; —OCORh; NHCORh; guanidinyl; carbamimidoyl or ureido;
each Rh is independently selected from hydrogen, a —C1-6 straight or branched-chain alkyl group, a —C3-C6 cycloalkyl group or phenyl, or when two Rh groups are present, said Rh groups may be taken in combination and represent a 4-6 membered saturated ring, optionally interrupted by one or two of O, S, SO2, —C(O)—, NH and NCH3;
each Q is selected from the group consisting of:
wherein.
a and b are 1, 2 or 3;
L− is a pharmaceutically acceptable counterion;
α is O, S or NRs;
β, δ, λ, μ, and σ are independently CRt, N or N+Rs, provided that no more than one of β, δ, λ, μ, and σ is N+Rs;
each Rs is independently selected from hydrogen; phenyl or C1-6 straight- or branched-chain alkyl, unsubstituted or substituted with one to four Ri groups;
each Rt is independently selected from hydrogen; halo; phenyl; —CN; —NO2; —NRuRv; —ORu; —SRu; —CONRuRv; —COORh; —SORu; —SO2Ru; —SO2NRuRv; —NRuSO2Rv; —CORu; —NRuCORv; —OCORu; —OCONRuRv; —NRuCO2Rv; —NRuCONRvRw; —OCO2Rv; —C1-6 straight- or branched-chain alkyl, unsubstituted or substituted with one to four Ri groups;
each Ru and Rv is independently selected from hydrogen or —C1-6 straight- or branched-chain alkyl, unsubstituted or substituted with one to four Ri groups or Ru and Rv together with any intervening atoms is a 4-6 membered saturated ring optionally interrupted by one or more of O, S, NRW or —C(O)—, the ring being unsubstituted or substituted with one to four Ri groups;
each Rw is independently selected from hydrogen; —C1-6 straight- or branched-chain alkyl, unsubstituted or substituted with one to four Ri groups; C3-6 cycloalkyl optionally substituted with one to four Ri groups; phenyl optionally substituted with one to four Ri groups, or heteroaryl optionally substituted with 1-4 Ri groups; or Rh and Rw taken together with any intervening atoms represent a 5-6 membered saturated ring, optionally interrupted by one or two of O, S, SO2, NH or NCH3;
each Rx is independently hydrogen or a C1-8 straight- or branched chain alkyl, optionally interrupted by one or two of O, S, SO, SO2, NRw, N+RhRw, or —C(O)—, said chain being unsubstituted or substituted with one to four of halo, CN, NO2, ORw, SRw, SORw, SO2Rw, NRhRw, N+(Rh)2Rw, —C(O)—Rw, C(O)NRhRw, SO2NRhRw, CO2Rw, OC(O)Rw, OC(O)NRhRw, NRhC(O)Rw, NRhC(O)NRhRw, or a phenyl or heteroaryl group which is in turn optionally substituted with from one to four Ri groups or with one to two C1-3 straight- or branched-chain alkyl groups, said alkyl groups being unsubstituted or substituted with one to four Ri groups;
each Ry and Rz is independently selected from hydrogen; phenyl; —C1-6 straight or branched chain alkyl, unsubstituted or substituted with one to four Ri groups, and optionally interrupted by O, S, NRw, N+RhRw or —C(O)— or Rx and Ry together with any intervening atoms is a 4-6 membered saturated ring optionally interrupted by O, S, SO2, NRw, N+RhRw or —C(O)—, unsubstituted or substituted with 1-4 Ri groups,
or, when Rx and Ry together are a 4-6 membered ring, Rz is an additional saturated 4-6 membered ring fused to the Rx and Ry ring, optionally interrupted by O, S, NRw or —C(O)—, the rings being unsubstituted or substituted with one to four Ri groups.

### Claim 2 (depends on 1)

The compound of claim 1 wherein the carbapenem is of the formula II,
or pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl;
Y1 is H or R2, wherein R2 is H or C1-C4 alky; and
Y2 is —(CH2)n-A, wherein n is 0-4 and A is —CN, —OR2, —SR2, —N(R2)2, CO2R2, CO)—N(R2), —CO)—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(—NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 3 (depends on 1)

The compound of claim 1 wherein the carbapenem is of the formula III,
pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl; and
Y is —(CH2)n-A, wherein n is 0-4 and A is —CN, —OR2, —SR2, —N(R2)2, CO2R2, C(═O)—N(R2), —C(═O(O)—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 4 (depends on 1)

The compound of claim 1 wherein the carbapenem is of the formula IV,
or pharmaceutically acceptable salts thereof, wherein:
R1 is H or methyl;
P is hydrogen or hydroxyl;
n=0-4; and
B is —OR2, —SR2, —N(R2)2, CO2R2, CO—N(R2), —CO—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein P′ is hydroxyl; R1 is methyl; n is 0 or 1; and B is CONH2, —CONHSO2NH2, NHSO2NH2, NH—C(═NH)—NH2 or —S—C(═NH)—NH2.

### Claim 6 (depends on 1)

The compound of claim 1 wherein the carbapenem is of the formula V,
or pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl;
Z is —O, —S, —N(R2); and
each Y3 and Y4 is independently hydrogen or —(CH2)n-A, wherein n=0-4 and A is selected from —N(R2)2, —CO2R2, —CO—N(R2)2, —CO—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is H or C1-C4 alkyl.

### Claim 7 (depends on 6)

The compound of claim 6 wherein: P′ is hydroxyl; R1 is methyl; Z is NH; and each Y3 and Y4 is independently hydrogen or —(CH2)n-A, wherein n=0-2 and A is —N(R2)2, —CON(R2)2, —CO—NHSO2NH2, or NHSO2NH2, wherein each R2 is hydrogen or methyl.

### Claim 8 (depends on 1)

The compound of claim 1 wherein the compound is compound 9,
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 9 (depends on 1)

The compound of claim 1 wherein the compound is compound 12:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 10 (depends on 1)

The compound of claim 1 wherein the compound is compound 15:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 11 (depends on 1)

The compound of claim 1 wherein the compound is compound 18:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 12 (depends on 1)

The compound of claim 1 wherein the compound is compound 21:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 13 (depends on 1)

The compound of claim 1 wherein the compound is compound 25:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 14 (depends on 1)

The compound of claim 1 wherein the compound is compound 28:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 15 (depends on 1)

The compound of claim 1 wherein the compound is compound 32:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 16 (depends on 1)

The compound of claim 1 wherein the compound is compound 34:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 17 (depends on 1)

The compound of claim 1 wherein the compound is compound 36:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 18 (depends on 1)

The compound of claim 1 wherein the compound is compound 39:
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the carbapenem is of the formula II,
or pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl;
Y1 is H or R2, wherein R2 is H or C1-C4 alky; and
Y2 is —(CH2)n-A, wherein n is 0-4 and A is —CN, —OR2, —SR2, —N(R2)2, CO2R2, CO)—N(R2), —CO)—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 21 (depends on 19)

The composition of claim 19, wherein the carbapenem is of the formula III,
or pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl; and
Y is —(CH2)n-A, wherein n is 0-4 and A is —CN, —OR2, —SR2, —N(R2)2, CO2R2, C(═O)—N(R2), —C(═O)—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 22 (depends on 19)

The composition of claim 19, wherein the carbapenem is of the formula IV,
or pharmaceutically acceptable salts thereof, wherein:
R1 is H or methyl;
P is hydrogen or hydroxyl;
n=0-4; and
B is —OR2, —SR2, —N(R2)2, CO2R2, CO—N(R2), —CO—NR2 SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 23 (depends on 22)

The composition of claim 22, wherein P′ is hydroxyl; R1 is methyl; n is 0 or 1; and B is CONH2, —CONHSO2NH2, NHSO2NH2, NH—C(═NH)—NH2 or —S—C(═NH)—NH2.

### Claim 24 (depends on 19)

The composition of claim 19, wherein the carbapenem is of the formula V,
or pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl;
Z is —O, —S, —N(R2); and
each Y3 and Y4 is independently hydrogen or —(CH2)n-A, wherein n=0-4 and A is selected from —N(R2)2, —CO2R2, —CO—N(R2)2, —CO—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is H or C1-C4 alkyl.

### Claim 25 (depends on 24)

The composition of claim 24, wherein: P′ is hydroxyl; R1 is methyl; Z is NH; and each Y3 and Y4 is independently hydrogen or —(CH2)n-A, wherein n=0-2 and A is —N(R2)2, —CON(R2)2, —CO—NHSO2NH2, or NHSO2NH2, wherein each R2 is hydrogen or methyl.

### Claim 26 (depends on 19)

The composition of claim 19, wherein the compound is selected from the group consisting of compound 9, 12, 15, 18, 21, 25, 28, 32, 34, 36 and 39
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

A method of preventing or treating an infection by a gram negative bacteria in a host comprising administering to the host a therapeutic amount of a compound of claim 1, optionally in a pharmaceutically acceptable carrier.

### Claim 28 (depends on 27)

The method of claim 27, wherein the carbapenem is of the formula II,
or pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl;
Y1 is H or R2, wherein R2 is H or C1-C4 alky; and
Y2 is —(CH2)n-A, wherein n is 0-4 and A is —CN, —OR2, —SR2, —N(R2)2, CO2R2, CO)—N(R2), —CO)—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 29 (depends on 27)

The method of claim 27, wherein the carbapenem is of the formula III,
or pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl; and
Y is —(CH2)n-A, wherein n is 0-4 and A is —CN, —OR2, —SR2, —N(R2)2, CO2R2, C(═O)—N(R2), —C(═O)—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 30 (depends on 27)

The method of claim 27, wherein the carbapenem is of the formula IV,
or pharmaceutically acceptable salts thereof, wherein:
R1 is H or methyl;
P is hydrogen or hydroxyl;
n=0-4; and
B is —OR2, —SR2, —N(R2)2, CO2R2, CO—N(R2), —CO—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is independently H or C1-C4 alkyl.

### Claim 31 (depends on 30)

The method of claim 30, wherein P′ is hydroxyl; R1 is methyl; n is 0 or 1; and B is CONH2, —CONHSO2NH2, NHSO2NH2, NH—C(═NH)—NH2 or —S—C(═NH)—NH2.

### Claim 32 (depends on 27)

The method of claim 27, wherein the carbapenem is of the formula V,
or pharmaceutically acceptable salts thereof, wherein:
R1 is hydrogen or methyl;
P is hydrogen or hydroxyl;
Z is —O, —S, —N(R2); and
each Y3 and Y4 is independently hydrogen or —(CH2)n-A, wherein n=0-4 and A is selected from —N(R2)2, —CO2R2, —CO—N(R2)2, —CO—NR2SO2N(R2)2, NR2SO2N(R2)2, NH—C(═NR2)—N(R2)2, —S—C(═NR2)—N(R2)2, wherein each R2 is H or C1-C4 alkyl.

### Claim 33 (depends on 32)

The method of claim 32, wherein: P′ is hydroxyl; R1 is methyl; Z is NH; and each Y3 and Y4 is independently hydrogen or —(CH2)n-A, wherein n=0-2 and A is —N(R2)2, —CON(R2)2, —CO—NHSO2NH2, or NHSO2NH2, wherein each R2 is hydrogen or methyl.

### Claim 34 (depends on 27)

The method of claim 27, wherein the compound is selected from the group consisting of compound 9, 12, 15, 18, 21, 25, 28, 32, 34, 36 and 39
or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 27)

The method of claim 27 wherein the host is a human.

### Claim 36 (depends on 27)

The method of claim 27 wherein the infection is by a drug resistant bacterial strain.

### Claim 37 (depends on 27)

The method of claim 27 wherein the infection is by a multiple-drug resistant strain.

### Claim 38 (depends on 27)

The method of claim 27 wherein the compound is administered in combination or alternation with at least one other antimicrobial agent.

### Claim 39 (depends on 27)

The method of claim 27 wherein the compound is administered in combination with a β-lactamase inhibiting agent.
